Author Correction | Open | Published:

Author Correction: Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y1 and P2Y12 receptors

Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-26577-0, published online 24 May 2018

This Article and the accompanying Supplementary Information file contain errors.

In Figure 2, the wrong µM symbol was used. The correct Figure 2 appears below as Figure 1.

Figure 1
figure1

Radioligand binding assays and functional assays showed that SAA and SAC can bind and antagonize both P2Y1 and P2Y12 receptors, while SAB can bind and antagonize only the P2Y12 receptor. (a) Displacement curves of SAA, SAB and SAC against [3H]2MeSADP binding to the P2Y12 receptor. (b) Functional antagonism by SAA of 2MeSADP-induced inhibition of foskolin-stimulated cAMP accumulation in U2OS cells expressing the P2Y12 receptor. (c) Schild plots of the antagonism of SAA, SAB and SAC at the P2Y12 receptors. (d) Displacement curves of SAA, SAB and SAC against [3H]2MeSADP binding to the P2Y1 receptor. (e) 2MeSADPinduced IP-1 accumulation in U2OS cells expressing the P2Y1 receptor (compared to MRS2500). (f) Schild plots of antagonism by SAA and SAC at the P2Y1 receptor. Results are expressed as mean ± SEM. The Ki values from binding experiments and KB values from Schild analyses of functional antagonism by SAA, SAB and SAC are listed in the text and are from at least three independent experiments. MRS, MRS2500; SAR, SAR216471.

In the Supplementary Information file, the title of Table S1 is incorrectly given as ‘SAA, SAB and SAC are not promiscuously binding compounds’. The correct Table S1 appears below as Table 1.

Table 1 Targets used in the off-target activities tested by the PDSP.

Finally, in the Supplementary Information file, there is a typographical error in Figure S4 and its accompanying legend where ‘Epinenohrineon’ should read ‘Epinephrine’. The correct Figure S4 appears below as Figure 2.

Figure 2
figure2

The functional activity of SAB on the adrenergic α1B receptor were tested by FLIPR assays. SAB did not show agonist activity on α1B, epinephrine is a control agonist (EC50 29.8 nM) (a). SAB did not show antagonist activity on α1B, WB4104 is a control antagonist (IC50 4.51 nM) (b).

Author information

Correspondence to Suwen Zhao.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.